This invention is directed to compounds of formula (I):

##STR00001##

where r, q, R, R.sup.2, R.sup.3, R.sup.4, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.7, R.sup.8, and R.sup.9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A.sub.4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

This invention is directed to compounds of formula (I):

##STR00001##

where r, q, R, R.sup.2, R.sup.3, R.sup.4, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.7, R.sup.8, and R.sup.9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A.sub.4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of Formula I, hydrates or pharmaceutically acceptable salts thereof. The compound of Formula I of the present invention is a potent cross-linking protein cleavage agent, has a stable structure, good physical and chemical properties, and good pharmacological activities, and is suitable for large scale production to obtain samples with stable, controllable and reliable quality, thereby being suitable for pharmaceutical development. ##STR00001##

The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of Formula I, hydrates or pharmaceutically acceptable salts thereof. The compound of Formula I of the present invention is a potent cross-linking protein cleavage agent, has a stable structure, good physical and chemical properties, and good pharmacological activities, and is suitable for large scale production to obtain samples with stable, controllable and reliable quality, thereby being suitable for pharmaceutical development. ##STR00001##

The present invention provides a compound that has an excellent control effect on arthropod pests, and is represented by formula (I) [wherein Q represents a group represented by Q1, or the like, n is 0, 1, or 2, R.sup.2 represents a C1-C6 alkyl group which may optionally have one or more halogen atoms, or the like, Y.sup.a represents an oxygen atom, a sulfur atom, or NR.sup.3a, G.sup.1 represents a nitrogen atom or CR.sup.5a, G.sup.2 represents a nitrogen atom or CR.sup.5b, A.sup.2 represents a nitrogen atom or CR.sup.4a, A.sup.3 represents a nitrogen atom or CR.sup.4b, A.sup.4 represents a nitrogen atom or CR.sup.4c, and R.sup.3a, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.5a, and R.sup.5b represent a C1-C6 chain hydrocarbon group or the like, and T represents a C1-C10 chain hydrocarbon group which may optionally have one or more halogen atoms, or the like]. ##STR00001##

The present invention provides a compound that has an excellent control effect on arthropod pests, and is represented by formula (I) [wherein Q represents a group represented by Q1, or the like, n is 0, 1, or 2, R.sup.2 represents a C1-C6 alkyl group which may optionally have one or more halogen atoms, or the like, Y.sup.a represents an oxygen atom, a sulfur atom, or NR.sup.3a, G.sup.1 represents a nitrogen atom or CR.sup.5a, G.sup.2 represents a nitrogen atom or CR.sup.5b, A.sup.2 represents a nitrogen atom or CR.sup.4a, A.sup.3 represents a nitrogen atom or CR.sup.4b, A.sup.4 represents a nitrogen atom or CR.sup.4c, and R.sup.3a, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.5a, and R.sup.5b represent a C1-C6 chain hydrocarbon group or the like, and T represents a C1-C10 chain hydrocarbon group which may optionally have one or more halogen atoms, or the like]. ##STR00001##

The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-κB signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.